Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 2

Status

Recruiting 4Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Breast Neoplasms 81Neoplasms 72Neoplasm Metastasis 63Melanoma 63Leukemia, Myeloid, Acute 58Ovarian Neoplasms 54Lymphoma, Non-Hodgkin 52Prostatic Neoplasms 50Colorectal Neoplasms 50Multiple Myeloma 49Glioblastoma 48Pancreatic Neoplasms 47Lung Neoplasms 45Recurrence 41Carcinoma, Renal Cell 40Squamous Cell Carcinoma of Head and Neck 37Leukemia, Lymphocytic, Chronic, B-Cell 37Triple Negative Breast Neoplasms 35Myelodysplastic Syndromes 30Lymphoma, Large B-Cell, Diffuse 28Glioma 28Stomach Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell 27Brain Neoplasms 27Lymphoma, Follicular 26Endometrial Neoplasms 26Lymphoma 25Carcinoma, Hepatocellular 24

Interventions

Nivolumab 1Ipilimumab 1E-7386 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Eisai Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡